摘要
目的观察晚期肝细胞癌（ＨＣＣ）患者采用抗ＣＤ３抗体激活的杀伤细胞（ＣＤ３ＡＫ）治疗的效果。方法５８例晚期ＨＣＣ患者分为三组，Ａ组［ＣＤ３ＡＫ＋肝动脉化学栓塞（ＴＡＣＥ）］２２例，Ｂ组（ＣＤ３ＡＫ）１５例，Ｃ组（ＴＡＣＥ）２１例。结果部分缓解率（ＰＲ）Ａ，Ｂ，Ｃ组分别为４５．５％、１３．３％（Ｐ＜０．０５）和１４．３％（Ｐ＜０．０５），中位生存期分别为１１．３月、４．９月（Ｐ＜０．０１）和４．１月（Ｐ＜０．０１），半年和１年生存率分别依次为６８．２％，３３．３％（Ｐ＜０．０５）和２３．８％以及４０．９％、６．６％（Ｐ＜０．０５）和９．５％（Ｐ＜０．０５）。
Objective:The therapeutic effectiveness of the CD 3AK (anti CD 3 antibody activated killer cell) plus TACE,the CD 3AK alone,and the TACE alone in treating advanced hepatocellular cancer (HCC) was compared.Methods: Clinical trial was performed 58 patients were divided into Group A (CD 3AK+TACE,22 patients),Group B(CD 3AK alone,15 patients) and Group C(TACE alone,21 patients) Results: The rates of remission were 45 5% in Group A,13 3% in Group B( P <0 05 in compare with Group A),and 14 3% in Group C( P <0 05). The mean surrival times were 11.3 months、4 9months( P <0 01) and 4 1months ( P <0 01) respectively. The survival rates at the 6 th month were 68 2%,33 3% ( P <0 05) and 23 8%( P <0 01) respectively,and at 12 th month were 40 9%,6 6% ( P <0 05) and 9 5%( P <0 05)respectively.Conclusions: The treatment with CD 3AK after TACE is more effective for advanced HCC than CD 3AK or TACE alone
出处
《肿瘤》
CAS
CSCD
北大核心
1997年第1期14-16,共3页
Tumor
关键词
肝肿瘤
免疫疗法
杀伤细胞
抗体激活
治疗
Liver neoplasms/immunotherapy Killer cells,Anti CD 3Ab activated Chemoembolizalion,therapeutic
